Related Experiment Video
Updated: Jul 18, 2026
A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice
Published on: January 23, 2016
Statins and solid organ transplantation
I F Gazi1, E N Liberopoulos, V G Athyros
1Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College of Medicine, University of London, Pond Street, London NW3 2QG, UK.
Insights
Statins are effective and safe for managing dyslipidemia in solid organ transplant recipients, improving survival and reducing cardiovascular events and rejection. Close monitoring for side effects is recommended due to interactions with immunosuppressants.
Area of Science:
- Medical Science
- Pharmacology
- Transplant Medicine
Background:
- Dyslipidemia is prevalent in solid organ transplant recipients.
- It is linked to chronic rejection, atherosclerosis, and increased cardiovascular disease (CVD) risk.
- CVD is a leading cause of death in transplant patients.
Purpose of the Study:
- To review the benefits of statins in solid organ transplant recipients (adults and children).
- To examine combination therapy with ezetimibe and statins.
- To assess the safety and efficacy of statins in this unique patient population.
Main Methods:
- Review of clinical trials and studies on statin use in transplant recipients.
- Analysis of data on dyslipidemia management, CVD events, rejection rates, and survival.
- Consideration of drug interactions, particularly with immunosuppressive therapy.
Main Results:
- Statins are efficient and safe for treating dyslipidemia in transplant patients.
- Statins demonstrated beneficial effects on long-term survival, CVD events, and rejection rates in most trials.
- Combination therapy with ezetimibe and statins was also considered.
Conclusions:
- Statins are recommended for dyslipidemic transplant patients at appropriate dosages.
- Close monitoring for adverse effects is crucial due to immunosuppressive therapy.
- Statins offer significant benefits for managing dyslipidemia and improving outcomes in transplant recipients.
Abstract:
Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...